Nov
9
2021
On demand

Automated cell expansion: Current technologies and trends

Over the past several years, cell therapy has seen explosive growth in the number and variety of applications and disease targets under exploration for commercialization, a trend that is unlikely to slow. The diversity of manufacturing strategies and technology to support this growth has also evolved, albeit more slowly. Cell therapy manufacturers now face a wider range of decisions when it comes to implementing automated solutions in their process. And committing to the wrong manufacturing technology early in commercialization can mean expensive, risky delays with late process transfers and comparability studies.In this webinar, we will discuss the cell expansion step of the manufacturing cycle, unpacking critical elements and trends to consider when choosing when and how to automate this lengthy, labor-intensive process:

  • When should therapy manufacturers automate their cell expansion?
  • What elements are essential for success when choosing a cell expansion platform?
  • What technologies are available for automated cell expansion?
  • What are future trends that may impact your cell expansion automation decisions today?

Dalip Sethi, PhD

Director, Scientific Affairs, Terumo BCT

Dalip Sethi currently serves as the scientific and clinical development lead for the Cell Therapy Technologies portfolio at Terumo BCT. He holds a doctorate degree and conducted post doctoral studies at Thomas Jefferson University, School of Medicine. 

Prior to Terumo BCT, Dalip was engaged in the development of technologies & methods for use in cell therapy applications. Throughout his career, Dalip has authored multiple scientific publications and is a co-inventor on several patents & patent applications.

Augustus Kilgore, PhD

Global Marketing Manager, Terumo BCT

Gus Kilgore is the global product manager for the Quantum Cell Expansion platform, part of the cell therapy technologies business at Terumo Blood and Cell Technologies. Prior to that, Gus was involved in cell collections on the Spectra Optia apheresis system, a technology adjacent to the cell therapy space. Gus holds a PhD in immunology, and has authored multiple scientific publications.

Kathie Schneider

Director, Global Commercial Lead, Terumo BCT

SPEAKERS

Gus Kilgore, PhD
Global Marketing Manager, Terumo BCT
Dalip Sethi, PhD
Director, Scientific Affairs, Terumo BCT
Kathie Schneider
Director, Global Commercial Lead, Terumo BCT

You might also like

Current technological trends and advancements in vector purification

C Gaskin,
A Saksule,
N Clement et al.
Chantelle Gaskin
Chantelle Gaskin
Field Applications Scientist, Thermo Fisher Scientific
Ashish Saksule
Ashish Saksule
Cell and Gene Therapy Process Development Lead, Takeda
Nathalie Clement, PhD
Nathalie Clement, PhD
Ying Cai, PhD
Ying Cai, PhD
Senior Director, Process Development, Ultragenyx Pharmaceutical
Matthew Roach
Matthew Roach
AAV Process Development Team Leader, Precision BioSciences
15 Dec 2021
14
Days
14
Hrs
31
Min
Register

Putting the patient first: New modalities of manufacturing for cell...

C White,
B Wang,
K Wang
Chelsea C. White III
Chelsea C. White III
Schneider National Chair of Transportation & Logistics, H. Milton Stewart School of Industrial & Systems Engineering, Georgia Institute of Technology
Professor Ben Wang
Professor Ben Wang
Gwaltney Chair in Manufacturing Systems, Executive Director, Georgia Institute of Technology
Dr. Kan Wang
Dr. Kan Wang
Senior Research Engineer, Georgia Tech Manufacturing Institute, Georgia Institute of Technology
9 Dec 2021
8
Days
14
Hrs
31
Min
Register

Enabling clinical grade manufacturing of gene-engineered NK cells

N Moker,
E Ullrich,
R Romee et al.
Nina Möker
Nina Möker
R&D Reagents Manager, Allogeneic Cell Therapy, Miltenyi Biotec
Prof. Dr. Evelyn Ullrich
Prof. Dr. Evelyn Ullrich
Arbeitsgruppe Zelluläre Immunologie, Universitätsklinikum, Frankfurt am Main (kgu.de)
Rizwan Romee, MD
Rizwan Romee, MD
Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute
Volker Huppert
Volker Huppert
Chief Development Officer Glycostem Therapeutics
30 November 2021
Watch now

Magnetic selection for consistent cellular starting material in autologous...

K Olsen,
R Perret,
Kenneth Olsen, PhD
Kenneth Olsen, PhD
Senior R&D Scientist, Personalized Medicine Business Unit, Lonza
 Rachel Perret, PhD
Rachel Perret, PhD
Team Leader, CAR T-cell Research Program, Malaghan Institute of Medical Research
23 November 2021
Watch now

Platform optimization for efficient AAV purification – insights from a CDMO

N Laroudie,
V Ravault,
Nicolas Laroudie
Nicolas Laroudie
Staff Scientist, Field Applications, Thermo Fisher Scientific
Vincent Ravault
Vincent Ravault
DSP Expert, Process Development and Industrialization Department, YposKesi
26 October 2021
Watch now